Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events
- PMID: 27083288
- DOI: 10.1016/j.kint.2016.01.014
Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events
Abstract
Cardiovascular disease is more common in patients with chronic kidney disease (CKD), and traditional risk factors do not adequately predict those at risk for cardiovascular (CV) events. Recent evidence suggests elevated trimethylamine N-oxide (TMAO), created by gut microflora from dietary L-carnitine and choline, is associated with CV events. We investigated the relationship of TMAO levels in patients with stages 3b and 4 CKD to ischemic CV events using the CanPREDDICT cohort, a Canada-wide observational study with prospective 3-year follow-up of adjudicated CV events. Baseline samples were obtained for 2529 CKD patients. TMAO, choline, and L-carnitine levels were measured using tandem mass spectrometry. Baseline median TMAO level was high for the whole cohort (20.41 μM; interquartile range [IQR]: 12.82-32.70 μM). TMAO was independently associated with CV events (hazard ratio 1.23; 95% confidence interval: 1.06-1.42 / 1 SD lnTMAO) after adjusting for all potential CV risk factors. Those in the highest TMAO quartile had significantly higher risk of CV events (adjusted hazard ratio 1.59; 95% confidence interval: 1.04-2.43; P = 0.0351) in the analysis of recurring ischemic events. Among those with stage 3b CKD (hazard ratio 1.45; 95% confidence interval: 1.12-1.87 / 1 SD lnTMAO), independent of kidney function, TMAO levels identified those at highest risk for events. Our results suggest that TMAO may represent a new potentially modifiable CV risk factor for CKD patients. Further studies are needed to determine sources of variability and if lowering of TMAO reduces CV risk in CKD.
Keywords: cardiovascular risk; chronic kidney disease; trimethylamine N-oxide.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.Circ Res. 2015 Jan 30;116(3):448-55. doi: 10.1161/CIRCRESAHA.116.305360. Epub 2014 Nov 5. Circ Res. 2015. PMID: 25599331 Free PMC article.
-
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease.PLoS One. 2016 Jan 11;11(1):e0141738. doi: 10.1371/journal.pone.0141738. eCollection 2016. PLoS One. 2016. PMID: 26751065 Free PMC article.
-
Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study.Clin Exp Nephrol. 2016 Oct;20(5):731-739. doi: 10.1007/s10157-015-1207-y. Epub 2015 Dec 16. Clin Exp Nephrol. 2016. PMID: 26676906 Free PMC article.
-
The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease.Kidney Int. 2017 Oct;92(4):809-815. doi: 10.1016/j.kint.2017.03.053. Epub 2017 Aug 12. Kidney Int. 2017. PMID: 28807612 Review.
-
Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet.J Ren Nutr. 2015 Nov;25(6):459-65. doi: 10.1053/j.jrn.2015.06.004. Epub 2015 Jul 31. J Ren Nutr. 2015. PMID: 26235933 Review.
Cited by
-
TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review.Front Pharmacol. 2022 Aug 12;13:929262. doi: 10.3389/fphar.2022.929262. eCollection 2022. Front Pharmacol. 2022. PMID: 36034781 Free PMC article. Review.
-
Trimethylamine N-Oxide and mortality in hemodialysis patients: like a mystery.Ren Fail. 2021 Dec;43(1):463-464. doi: 10.1080/0886022X.2021.1890618. Ren Fail. 2021. PMID: 33657973 Free PMC article. No abstract available.
-
Circulating trimethylamine N-oxide in association with diet and cardiometabolic biomarkers: an international pooled analysis.Am J Clin Nutr. 2021 May 8;113(5):1145-1156. doi: 10.1093/ajcn/nqaa430. Am J Clin Nutr. 2021. PMID: 33826706 Free PMC article.
-
The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis.Int J Mol Sci. 2021 Dec 15;22(24):13477. doi: 10.3390/ijms222413477. Int J Mol Sci. 2021. PMID: 34948275 Free PMC article.
-
Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system.Exp Biol Med (Maywood). 2020 Jan;245(2):166-175. doi: 10.1177/1535370219900898. Epub 2020 Jan 16. Exp Biol Med (Maywood). 2020. PMID: 31948289 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical